Role of Interleukin 28B polymorphisms in response to Interferon based therapy for hepatitis C virus clearance.

Role of Interleukin 28B polymorphisms in response to Interferon based therapy for hepatitis C virus clearance. Curr Drug Metab. 2018 Jan 28;: Authors: Asthana M, Sahu SK, Kumar A, Mohanty S, Chakrabarti S, Das P, Chattopadhya NR, Chatterjee K, Singh SP, Rajasubramaniam S, Choudhuri T Abstract Interleukin-28B (IL28B) locus on a human chromosomal region 19q13 is responsible for immune protection against viruses. IL28B in hepatitis C virus (HCV) infection determines the fate of infection towards causing spontaneous clearance or chronic liver infection. Choice of treatment in chronic hepatitis C infection includes use of direct acting antivirals, pegylated-interferon (PEG-IFN) or ribavirin (RBV) therapy. Interferon free regimens are also suggested to be useful in drug resistant patients. Genome-wide association studies (GWAS), comprehensive meta-analysis and independent case-control studies in different ethnic populations have demonstrated association between certain Il-28B polymorphisms and its effect on the response to PEG-IFN-RBV therapy in HCV patients. .Further, IL28B SNPs and its association with the SVR rate in HCV patients on PEG-IFN-RBV therapy is well documented. Thus, IL28B genotyping may be used as a predictor of IFN-based therapy outcomes, and a strategy for developing personalized treatment of hepatitis C patients. PMID: 29380700 [PubMed - as supplied by publisher]
Source: Current Drug Metabolism - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Metab Source Type: research